Joshua D Woolley
Overview
Explore the profile of Joshua D Woolley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aday J, Skiles Z, Eaton N, Fredenburg L, Pleet M, Mantia J, et al.
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(1):27-37.
PMID: 40047007
Background: An emerging controversy in psychedelic therapy regards the appropriateness or necessity of psychedelic therapists having personal experience using psychedelics themselves. Although there are a number of potential advantages and...
2.
Brown C, De Coster L, Lee J, Lin L, Mathalon D, Woolley J
Psychoneuroendocrinology
. 2024 Nov;
172:107228.
PMID: 39581167
Empathic accuracy, the ability to accurately understand other people's emotions, is a complex social cognitive skill that is often impaired in schizophrenia and this impairment is associated with poor functional...
3.
Peled-Avron L, Aday J, Kalafateli A, Hamilton H, Woolley J
Front Psychiatry
. 2024 Jun;
15:1431389.
PMID: 38915850
No abstract available.
4.
Aday J, Horton D, Fernandes-Osterhold G, ODonovan A, Bradley E, Rosen R, et al.
Psychopharmacology (Berl)
. 2024 May;
241(8):1517-1526.
PMID: 38782821
Rationale: Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance...
5.
Sakai K, Bradley E, Zamaria J, Agin-Liebes G, Kelley D, Fish A, et al.
Psychopharmacology (Berl)
. 2024 Apr;
241(8):1617-1630.
PMID: 38687360
Rationale: Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin...
6.
Mitchell J, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al.
Focus (Am Psychiatr Publ)
. 2023 Jul;
21(3):315-328.
PMID: 37404971
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3...
7.
Aday J, Carhart-Harris R, Woolley J
JAMA Psychiatry
. 2023 Apr;
80(6):533-534.
PMID: 37074690
No abstract available.
8.
Chuang B, Campellone T, Woolley J
Compr Psychoneuroendocrinol
. 2022 Jun;
4:100011.
PMID: 35755629
Schizophrenia-spectrum disorders (SSD) are associated with deficits in emotional prosody recognition. Whether administration of oxytocin can improve emotional prosody recognition accuracy in SSD is unknown. Sixty individuals with SSD and...
9.
Nishimi K, Borsari B, Tripp P, Jiha A, Dolsen E, Woolley J, et al.
J Psychiatr Res
. 2022 May;
151:399-404.
PMID: 35588548
Understanding correlates of COVID-19 vaccine intentions is critical for increasing vaccine uptake. Given associations of trauma exposure and posttraumatic stress disorder (PTSD) with alterations in threat sensitivity and health behaviors,...
10.
Aday J, Heifets B, Pratscher S, Bradley E, Rosen R, Woolley J
Psychopharmacology (Berl)
. 2022 Apr;
239(6):1989-2010.
PMID: 35359159
Rationale: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and...